Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib in relapsed or refractory adult B-cell ALL
NCT04803123Phase 1Terminated
- Start
- Jun 2021
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of copanlisib in acute lymphoblastic leukemia (ALL). Primary endpoint: Alpha-6 integrin expression levels in leukemic blasts at 1 year. Started Jun 2021; status: terminated.
02
Drugs
copanlisib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04803123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04803123.